T-Cell Receptor Therapy in the Treatment of Ovarian Cancer: A Mini Review

T-Cell Receptor Therapy in the Treatment of Ovarian Cancer: A Mini Review

Ovarian cancer, in particularly high-grade serous ovarian cancer (HGSOC) and ovarian carcinosarcoma (OCS), are highly aggressive and deadly female cancers with limited treatment options. These tumors are generally unresponsive to immune check-point inhibitor (ICI) therapy and are referred to as immu...

Bibliografske podrobnosti
Main Authors:	Jessica W. Y. Wu, Sudiksha Dand, Lachlan Doig, Anthony T. Papenfuss, Clare L. Scott, Gwo Ho, Joshua D. Ooi
Format:	Article
Jezik:	English
Izdano:	Frontiers Media S.A. 2021-04-01
Serija:	Frontiers in Immunology
Teme:	T-cell receptor tumor neoantigen cell-based therapy ovarian cancer immunotherapy
Online dostop:	https://www.frontiersin.org/articles/10.3389/fimmu.2021.672502/full

Podobne knjige/članki

A library-based screening method identifies neoantigen-reactive T cells in peripheral blood prior to relapse of ovarian cancer
od: Spencer D. Martin, et al.
Izdano: (2018-01-01)

A Phase I/II trial comparing autologous dendritic cell vaccine pulsed either with personalized peptides (PEP-DC) or with tumor lysate (OC-DC) in patients with advanced high-grade ovarian serous carcinoma
od: Apostolos Sarivalasis, et al.
Izdano: (2019-11-01)

Neoantigen‐reactive T cell: An emerging role in adoptive cellular immunotherapy
od: Yicheng Zhu, et al.
Izdano: (2021-06-01)

Efficient identification of neoantigen-specific T-cell responses in advanced human ovarian cancer
od: Song Liu, et al.
Izdano: (2019-06-01)

Rationale for the Use of Homologous Recombination Proficient Molecular Profile as a Biomarker for Therapeutic Targeting in Ovarian Cancer
od: John Nemunaitis, et al.
Izdano: (2023-09-01)

Neoantigens retention in patient derived xenograft models mediates autologous T cells activation in ovarian cancer
od: Muzamil Yaqub Want, et al.
Izdano: (2019-06-01)

The frequency of neoantigens per somatic mutation rather than overall mutational load or number of predicted neoantigens per se is a prognostic factor in ovarian clear cell carcinoma
od: Hirokazu Matsushita, et al.
Izdano: (2017-08-01)

Artificial Mini Dendritic Cells Boost T Cell–Based Immunotherapy for Ovarian Cancer
od: Shanshan Cheng, et al.
Izdano: (2020-04-01)

Machine Learning for Cancer Immunotherapies Based on Epitope Recognition by T Cell Receptors
od: Anja Mösch, et al.
Izdano: (2019-11-01)

T cell therapy targeting a public neoantigen in microsatellite instable colon cancer reduces in vivo tumor growth
od: Else M. Inderberg, et al.
Izdano: (2017-04-01)

Neoantigen Specific T Cells Derived From T Cell-Derived Induced Pluripotent Stem Cells for the Treatment of Hepatocellular Carcinoma: Potential and Challenges
od: Fei Lu, et al.
Izdano: (2021-05-01)

Niraparib plays synergistic antitumor effects with NRT in a mouse ovarian cancer model with HRP
od: Jiefang Lu, et al.
Izdano: (2024-11-01)

Neoantigens in Hematologic Malignancies
od: Melinda A. Biernacki, et al.
Izdano: (2020-02-01)

Recent Advances in Targeting CD8 T-Cell Immunity for More Effective Cancer Immunotherapy
od: Aurélie Durgeau, et al.
Izdano: (2018-01-01)

Adoptive neoantigen-reactive T cell therapy: improvement strategies and current clinical researches
od: Ruichen Huang, et al.
Izdano: (2023-04-01)

Germinal center reactions in tertiary lymphoid structures associate with neoantigen burden, humoral immunity and long-term survivorship in pancreatic cancer
od: Andrew J. Gunderson, et al.
Izdano: (2021-01-01)

T cell receptors specific for an imatinib-induced mutation in BCR-ABL for adoptive T cell therapy
od: Meng-Tung Hsu, et al.
Izdano: (2025-01-01)

Personal Neoantigens From Patients With NSCLC Induce Efficient Antitumor Responses
od: Wei Zhang, et al.
Izdano: (2021-04-01)

Neoantigens: new hope for cancer therapy
od: Yitong Hu, et al.
Izdano: (2025-03-01)

The Landscape of Tumor-Specific Antigens in Colorectal Cancer
od: Nurul Ainaa Adilah Rus Bakarurraini, et al.
Izdano: (2020-07-01)

Structural basis for T cell recognition of cancer neoantigens and implications for predicting neoepitope immunogenicity
od: Roy A. Mariuzza, et al.
Izdano: (2023-11-01)

Neoantigens and their clinical applications in human gastrointestinal cancers
od: Zahra Shokati Eshkiki, et al.
Izdano: (2022-09-01)

Genomics meets immunity in pancreatic cancer: Current research and future directions for pancreatic adenocarcinoma immunotherapy
od: Jacob S. Bowers, et al.
Izdano: (2019-08-01)

Late-differentiated effector neoantigen-specific CD8+ T cells are enriched in peripheral blood of non-small cell lung carcinoma patients responding to atezolizumab treatment
od: Michael Fehlings, et al.
Izdano: (2019-09-01)

Poly-specific neoantigen-targeted cancer vaccines delay patient derived tumor growth
od: Luigi Aurisicchio, et al.
Izdano: (2019-02-01)

Determinants for Neoantigen Identification
od: Andrea Garcia-Garijo, et al.
Izdano: (2019-06-01)

Neo‐Antigen‐Reactive T Cells Immunotherapy for Colorectal Cancer: A More Personalized Cancer Therapy Approach
od: Guan‐Liang Chen, et al.
Izdano: (2023-11-01)

Current Trends in Neoantigen-Based Cancer Vaccines
od: Szu-Ying Ho, et al.
Izdano: (2023-03-01)

Promising New Tools for Targeting p53 Mutant Cancers: Humoral and Cell-Based Immunotherapies
od: Vitaly Chasov, et al.
Izdano: (2021-08-01)

Therapeutic strategies to enhance immune response induced by multiple myeloma cells
od: Zhaoyun Liu, et al.
Izdano: (2023-05-01)

Advanced HCC Patient Benefit From Neoantigen Reactive T Cells Based Immunotherapy: A Case Report
od: Chenxi Liu, et al.
Izdano: (2021-07-01)

The Neoantigen Landscape of Mycosis Fungoides
od: Arunima Sivanand, et al.
Izdano: (2020-11-01)

The Role of Neoantigens in Cancer Immunotherapy
od: Yueting Zhu, et al.
Izdano: (2021-08-01)

Advanced Pancreatic Cancer Patient Benefit From Personalized Neoantigen Nanovaccine Based Immunotherapy: A Case Report
od: Jie Shao, et al.
Izdano: (2022-02-01)

Neoantigen immunotherapy: a novel treatment for bladder cancer
od: Ruiyang Lv, et al.
Izdano: (2025-01-01)

Tumor neoantigens and tumor immunotherapies
od: Wang Jiani, et al.
Izdano: (2024-04-01)

Computational cancer neoantigen prediction: current status and recent advances
od: G. Fotakis, et al.
Izdano: (2021-12-01)

Neoantigens and the tumor microenvironment play important roles in the prognosis of high-grade serous ovarian cancer
od: Hua Yang, et al.
Izdano: (2022-01-01)

Efficacy and safety of PD-1 blockade-activated neoantigen specific cellular therapy for advanced relapsed non-small cell lung cancer
od: Yun Qiao, et al.
Izdano: (2025-01-01)

Editorial: Autoimmune Diabetes: Molecular Mechanisms and Neoantigens
od: Sally C. Kent, et al.
Izdano: (2022-02-01)